Linked Data API

Show Search Form

Search Results

386886
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Bone Marrow Disorders more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether they will place in the Library of the House any publications resulting from the phase 3 clinical trials approved for the potential treatment of systemic amyloidosis or multiple myeloma; and what is the National Institute of Health Research’s assessment of progress in these areas. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL995 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL996 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.197Zmore like thismore than 2015-07-14T15:34:29.197Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386887
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government whether there are currently any trials for systemic amyloidosis in humans being conducted by the National Institute of Health Research charities or the commercial sector. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL996 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL997 more like this
star this property question first answered
less than 2015-07-14T15:34:29.297Zmore like thismore than 2015-07-14T15:34:29.297Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
386888
star this property registered interest false more like this
star this property date less than 2015-07-01more like thismore than 2015-07-01
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Amyloidosis more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government which of the four phase 2 or 3 clinical trials for systemic amyloidosis approved since 2004 are still ongoing; and whether any of the trials have produced sufficient positive outcomes to encourage commercial development. more like this
star this property tabling member printed
Lord Willis of Knaresborough more like this
star this property uin HL997 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-14more like thismore than 2015-07-14
star this property answer text <p>There are four trials for systemic amyloidosis that are designated as ‘ongoing’ in the United Kingdom. These are being conducted by two commercial sponsors, Millennium Pharmaceuticals Inc and A.T. Development Switzerland Sarl (two studies), and one non-commercial sponsor, European Myeloma Network.</p><p> </p><p> </p><p> </p><p>Clinical trial sponsors are required to publish a summary of their trial results to the EU Clinical Trials Register within one year of their trial completing. At that point, these results will become publically available on the EU Clinical Trials Register</p><p> </p><p> </p><p> </p><p>The Department of Health, which funds the National Institute for Health Research (NIHR), is a member of the National Cancer Research Institute (NCRI). NCRI Clinical Studies Groups (CSGs) bring together clinicians, scientists, statisticians and lay representatives to coordinate development of a strategic portfolio of trials within their field. All CSGs interact with clinical research networks, funders (including NIHR) and researchers to develop studies aimed at improving outcomes for patients. The Haematological Oncology CSG has a Myeloma Subgroup and its 2013-14 annual report that includes an assessment of progress in these areas is attached and available on the NCRI website at:</p><p> </p><p><a href="http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf" target="_blank">http://csg.ncri.org.uk/wp-content/uploads/2014/11/NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf</a>.</p><p> </p><p> </p><p> </p><p>We cannot comment on commercial considerations. When the results are known, the commercial potential of these trial’s products will be a matter for the respective trial sponsors.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN
HL995 more like this
HL996 more like this
star this property question first answered
less than 2015-07-14T15:34:29.553Zmore like thismore than 2015-07-14T15:34:29.553Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
star this property attachment
1
star this property file name NCRI-Haem-Onc-CSG-Annual-Report-2013-14.pdf more like this
star this property title 2013-14 Annual Report more like this
unstar this property tabling member
4151
unstar this property label Biography information for Lord Willis of Knaresborough more like this
518800
star this property registered interest false more like this
star this property date less than 2016-05-18more like thismore than 2016-05-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Prime Minister: Ministerial Policy Advisers more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what action they are taking to ensure that NICE guidance is followed in the use of faecal microbiota transplants in the treatment of recurrent Clostridium difficile. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL94 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-05-26more like thismore than 2016-05-26
star this property answer text <p>The National Institute for Health and Care Excellence has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection under the interventional procedure programme. This programme makes recommendations about the safety of the procedures and how well they work. However the guidance does not constitute a direction to National Health Service trusts to provide the interventions. Decisions about whether to provide a treatment are taken locally.</p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL97 more like this
star this property question first answered
less than 2016-05-26T16:29:01.177Zmore like thismore than 2016-05-26T16:29:01.177Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
386467
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Pancreatic Cancer: Nurses more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what steps they are taking to ensure that all pancreatic cancer patients have access to a clinical nurse specialist. more like this
star this property tabling member printed
Lord Aberdare more like this
star this property uin HL962 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
star this property answer text <p>NHS England has a published service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>Patients being treated at cancer units should have access to an upper gastrointestinal cancer nurse. All district general hospitals should have such a person in post. If the patient is transferred to a cancer centre they should then have access to a pancreatic nurse specialist. This person should see every patient and become their key worker.</p><p> </p><p> </p><p> </p><p>Patients with suspected pancreatic cancer are usually first investigated by an ultrasound scan. If this shows biliary dilatation, or anything else suspicious, the patient should then be sent for a pancreas protocol computerised tomography scan which is the best investigation for identifying pancreatic cancer.</p><p> </p><p> </p><p> </p><p>Increasing the capacity of diagnostic and imaging services is clearly recognised as a priority for the National Health Service and it is has been raised as a key issue by the independent Cancer Taskforce, as well as by the Cancer Waiting Times Taskforce. We expect a new cancer strategy to be published this summer which will set out the strategy for the system for the next five years and will include consideration of the whole cancer pathway, including the capacity of diagnostic services.</p><p> </p><p> </p><p> </p><p>In addition, NHS England is testing various approaches to new models of care which could potentially deliver improved access to diagnostic services for cancer patients, including those with pancreatic cancer.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL963 more like this
star this property question first answered
less than 2015-07-09T12:43:47.243Zmore like thismore than 2015-07-09T12:43:47.243Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
unstar this property tabling member
3898
unstar this property label Biography information for Lord Aberdare more like this
386468
star this property registered interest false more like this
star this property date less than 2015-06-30more like thismore than 2015-06-30
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Pancreatic Cancer: Tomography more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what plans they have to increase the capacity of imaging services available to pancreatic cancer patients across the National Health Service, including computerised tomography scans. more like this
star this property tabling member printed
Lord Aberdare more like this
star this property uin HL963 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2015-07-09more like thismore than 2015-07-09
star this property answer text <p>NHS England has a published service specification for pancreatic cancer which clearly defines what it expects to be in place for providers to offer evidence-based, safe and effective pancreatic cancer services. This service specification has been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe core and developmental service standards.</p><p> </p><p> </p><p> </p><p>Patients being treated at cancer units should have access to an upper gastrointestinal cancer nurse. All district general hospitals should have such a person in post. If the patient is transferred to a cancer centre they should then have access to a pancreatic nurse specialist. This person should see every patient and become their key worker.</p><p> </p><p> </p><p> </p><p>Patients with suspected pancreatic cancer are usually first investigated by an ultrasound scan. If this shows biliary dilatation, or anything else suspicious, the patient should then be sent for a pancreas protocol computerised tomography scan which is the best investigation for identifying pancreatic cancer.</p><p> </p><p> </p><p> </p><p>Increasing the capacity of diagnostic and imaging services is clearly recognised as a priority for the National Health Service and it is has been raised as a key issue by the independent Cancer Taskforce, as well as by the Cancer Waiting Times Taskforce. We expect a new cancer strategy to be published this summer which will set out the strategy for the system for the next five years and will include consideration of the whole cancer pathway, including the capacity of diagnostic services.</p><p> </p><p> </p><p> </p><p>In addition, NHS England is testing various approaches to new models of care which could potentially deliver improved access to diagnostic services for cancer patients, including those with pancreatic cancer.</p><p> </p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL962 more like this
star this property question first answered
less than 2015-07-09T12:43:47.337Zmore like thismore than 2015-07-09T12:43:47.337Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
unstar this property tabling member
3898
unstar this property label Biography information for Lord Aberdare more like this
518801
star this property registered interest false more like this
star this property date less than 2016-05-18more like thismore than 2016-05-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Prime Minister: Ministerial Policy Advisers more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the outcome and cost effectiveness of the use of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL95 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-05-26more like thismore than 2016-05-26
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection. NICE has recommended that the procedure is safe enough for use in the National Health Service, but no assessment of its cost effectiveness has been made by NICE.</p><p> </p><p>Data on the uptake by the NHS of faecal microbiota transplants in the treatment of recurrent <em>Clostridium difficile</em> is not collected centrally.</p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL96 more like this
star this property question first answered
less than 2016-05-26T16:25:27.557Zmore like thismore than 2016-05-26T16:25:27.557Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
518802
star this property registered interest false more like this
star this property date less than 2016-05-18more like thismore than 2016-05-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Burial and Cremation more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what assessment they have made of the rate of uptake by the NHS of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL96 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-05-26more like thismore than 2016-05-26
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection. NICE has recommended that the procedure is safe enough for use in the National Health Service, but no assessment of its cost effectiveness has been made by NICE.</p><p> </p><p>Data on the uptake by the NHS of faecal microbiota transplants in the treatment of recurrent <em>Clostridium difficile</em> is not collected centrally.</p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL95 more like this
star this property question first answered
less than 2016-05-26T16:25:27.73Zmore like thismore than 2016-05-26T16:25:27.73Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
518803
star this property registered interest false more like this
star this property date less than 2016-05-18more like thismore than 2016-05-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Prime Minister: Ministerial Policy Advisers more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what action they are taking to ensure that NICE guidance is followed in the use of faecal microbiota transplants in the treatment of recurrent Clostridium difficile infections. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL97 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-05-26more like thismore than 2016-05-26
star this property answer text <p>The National Institute for Health and Care Excellence has produced guidance on faecal microbiota transplant for recurrent <em>Clostridium difficile</em> infection under the interventional procedure programme. This programme makes recommendations about the safety of the procedures and how well they work. However the guidance does not constitute a direction to National Health Service trusts to provide the interventions. Decisions about whether to provide a treatment are taken locally.</p> more like this
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL94 more like this
star this property question first answered
less than 2016-05-26T16:29:01.247Zmore like thismore than 2016-05-26T16:29:01.247Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
unstar this property tabling member
2024
unstar this property label Biography information for Lord Hunt of Kings Heath more like this
518798
star this property registered interest false more like this
star this property date less than 2016-05-18more like thismore than 2016-05-18
star this property answering body
Department of Health more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Asylum: Deportation more like this
star this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords more like this
star this property question text To ask Her Majesty’s Government what action they are taking to ensure that the NHS supply chain does not include products that are produced with forced labour or modern versions of slavery. more like this
star this property tabling member printed
Lord Crisp more like this
star this property uin HL92 more like this
unstar this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2016-05-25more like thismore than 2016-05-25
star this property answer text <p>The Department has worked with its national contracting and logistics partner, NHS Supply Chain to develop a range of ethical procurement interventions that increase the scrutiny applied to suppliers, based on the risks presented.</p><p> </p><p>All suppliers contracted by NHS Supply Chain are required to adhere to the <em>NHS Supply Chain – Supplier Code of Conduct</em>. A copy of the Code of Conduct is attached.</p><p> </p><p>This code of conduct includes requirements for suppliers to work in line with the United Nations Universal Declaration of Human Rights and the International Labour Organisation Declaration on Fundamental Principles and Rights at Work, and makes specific reference to forced and compulsory labour. The Supplier Code of Conduct has been a contractual requirement of all Framework Agreements since 2009.</p><p> </p><p>For categories of products where the risk of labour standards abuses has been assessed as high, by the nature of the manufacturing processes, employment practices or location, NHS Supply Chain require all suppliers to implement a Labour Standards Assurance System to specified standards.</p><p> </p><p>NHS Supply Chain continually review the wider contract portfolio, and where appropriate, the Labour Standards Assurance System requirements will be applied to new contract areas.</p><p> </p><p>Contract terms will require suppliers to implement and improve their Labour Standards Assurance System, in line with stipulated milestones, during the life of the framework agreement.</p><p> </p><p>Suppliers are contractually required to evidence compliance by providing details of independent third party audits conducted on their Assurance System.</p><p> </p><p>Where suppliers do not meet the specified standard within the stipulated timescales, their contract will be suspended in the first instance, and then terminated if remediation actions are not undertaken in a suitably timely manner.</p><p> </p><p>NHS Supply Chain provides support for suppliers required to implement a labour standards assurance system with webinars that provide access to expert support and capability building material.</p><p> </p><p>In relation to the British Medical Association (BMA) report <em>In Good Hands</em>, all suppliers awarded on the current Framework Agreement for Examination and Sterile Surgical Gloves are subject to the NHS Supply Chain Code of Conduct and contractual requirements to operate a Labour Standards Assurance System.</p><p> </p><p>Since the framework agreement launched in December 2015, a webinar workshop has been held with all suppliers to explain the Labour Standards Assurance System and implications of the Modern Slavery Act.</p><p> </p><p>Of the manufacturers named in the BMA report, two are currently awarded under the NHS Supply Chain national framework agreement for medical gloves.</p><p> </p><p>In both cases the Department in conjunction with NHS Supply Chain has investigated the allegations thoroughly by working with specialist independent third party audit bodies, who have undertaken assessments at the identified facilities.</p><p> </p><p>Audit findings have not identified any specific cases of slavery or human trafficking, or any serious systemic abuses of worker or human rights, however, improvements in management procedures, communications and training were recommended to reduce the potential for abuses to arise.</p><p> </p><p>Both suppliers have acknowledged these findings and have agreed actions, as part of contractual remediation plans, to address these.</p>
star this property answering member printed Lord Prior of Brampton more like this
star this property grouped question UIN HL93 more like this
star this property question first answered
less than 2016-05-25T15:19:32.327Zmore like thismore than 2016-05-25T15:19:32.327Z
star this property answering member
127
star this property label Biography information for Lord Prior of Brampton remove filter
star this property attachment
1
star this property file name HL92 and HL93 - NHS Supply Chain Supplier Code of Conduct.pdf more like this
star this property title NHS Supply Chain Code of Conduct more like this
unstar this property tabling member
3783
unstar this property label Biography information for Lord Crisp more like this